| Literature DB >> 29642369 |
Suradet Buttachon1,2, Alice A Ramos3,4, Ângela Inácio5,6, Tida Dethoup7, Luís Gales5,8, Michael Lee9, Paulo M Costa10,11, Artur M S Silva12, Nazim Sekeroglu13, Eduardo Rocha14,15, Madalena M M Pinto16,17, José A Pereira18,19, Anake Kijjoa20,21.
Abstract
A previously unreported bis-indolyl benzenoid, candidusin D (2e) and a new hydroxypyrrolidine alkaloid, preussin C (5b) were isolated together with fourteen previously described compounds: palmitic acid, clionasterol, ergosterol 5,8-endoperoxides, chrysophanic acid (1a), emodin (1b), six bis-indolyl benzenoids including asterriquinol D dimethyl ether (2a), petromurin C (2b), kumbicin B (2c), kumbicin A (2d), 2″-oxoasterriquinol D methyl ether (3), kumbicin D (4), the hydroxypyrrolidine alkaloid preussin (5a), (3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6) and 4-(acetylamino) benzoic acid (7), from the cultures of the marine sponge-associated fungus Aspergillus candidus KUFA 0062. Compounds 1a, 2a-e, 3, 4, 5a-b, and 6 were tested for their antibacterial activity against Gram-positive and Gram-negative reference and multidrug-resistant strains isolated from the environment. Only 5a exhibited an inhibitory effect against S. aureus ATCC 29213 and E. faecalis ATCC29212 as well as both methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) strains. Both 1a and 5a also reduced significant biofilm formation in E. coli ATCC 25922. Moreover, 2b and 5a revealed a synergistic effect with oxacillin against MRSA S. aureus 66/1 while 5a exhibited a strong synergistic effect with the antibiotic colistin against E. coli 1410/1. Compound 1a, 2a-e, 3, 4, 5a-b, and 6 were also tested, together with the crude extract, for cytotoxic effect against eight cancer cell lines: HepG2, HT29, HCT116, A549, A 375, MCF-7, U-251, and T98G. Except for 1a, 2a, 2d, 4, and 6, all the compounds showed cytotoxicity against all the cancer cell lines tested.Entities:
Keywords: Aspergillaceae; Aspergillus candidus; antibacterial activity; bis-indolyl benzenoids; cytotoxicity; hydroxypyrrolidine; sponge-associated fungus
Mesh:
Substances:
Year: 2018 PMID: 29642369 PMCID: PMC5923406 DOI: 10.3390/md16040119
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of some secondary metabolites isolated from the cultures of the marine sponge-associated fungus A. candidus KUFA 0062.
1H and 13C NMR (DMSO, 300.13 and 75.4 MHz) and HMBC assignment for 2e.
| Position | δC, Type | δH, ( |
|---|---|---|
| 1, 2, 4, 5 | 147.6, C | - |
| 3, 6 | 120.0, C | - |
| NH-1′, 1″ | - | 11.15, d (2.2) |
| 2′, 2″ | 126.0, CH | 7.43, d (2.5) |
| 3′, 3″ | 106.7, C | - |
| 4′, 4″ | 102.1, CH | 6.88, d (2.5) |
| 5′, 5″ | 153.1, C | - |
| 6′, 6″ | 110.9, CH | 6.78, dd (8.8, 2.5) |
| 7′, 7″ | 111.9, CH | 7.33, d (8.8) |
| 8′, 8″ | 131.0, C | - |
| 9′, 9″ | 127.7 | - |
| OCH3-1, 2, 4, 5 | 60.3, CH3 | 3.46, s |
| OCH3-5, 5′ | 55.3, CH2 | 3.72, s |
Figure 2ORTEP (Oak Ridge Thermal-Ellipsoid Plot Program) view of 3.
1H and 13C NMR of 5a (DMSO, 300.13 and 75.4 MHz) and 5b (DMSO, 300.13 and 75.4 MHz) and HMBC and NOESY assignments for 5b.
| 5a (DMSO, 300.13 and 75.4 MHz) | 5b (DMSO, 500.13 and 125.4 MHz) | ||||||
|---|---|---|---|---|---|---|---|
| Position | δC, Type | δH, ( | δC, Type | δH, ( | COSY | HMBC | NOESY |
| 1a | 30.6, CH2 | 3.69, dd (13.0, 9.4) | 31.3, CH2 | 3.11, dd (13.8, 8.0) | H-1b, 2 | C-2, 3 | H-1b, 2′, 6′ |
| b | 3.13, dd (12.7, 4.8) | 2.94, dd (13.8, 6.6) | H-1a, 2 | C-2, 3 | H-1a | ||
| 2 | 76.0, CH | 3.09, q (4.7) | 65.5, CH | 3.46, m | H-1b, 1b, 3 | C-1 | H-3 |
| 3 | 68.6, CH | 4.22, m | 68.7, CH | 4.09, dd (7.9, 4.0) | H-2, 4β, OH-3 | C-2, 5 | H-2, H-4β, OH-3 |
| 4α | 38.8, CH2 | 2.06, ddd (14.8, 9.3, 2.1) | 38.5, CH2 | 1.58, dd (13.9, 5.8) | H-3, 5 | C-3, 5, 6 | H-3, 4β, 5 |
| β | 2.69, ddd (15.0, 8.2, 8.2) | 2.37, ddd (13.9, 9.9, 5.5) | H-5 | C-2, 3, 5, 6 | H-4α, H-3 | ||
| 5 | 69.3, CH | 2.92,m | 57.6, CH | 3.41, m | H-4β, 4α, 6 | C-4, 6, 7 | |
| 6 | 30.1, CH2 | 2.25, m | 33.6, CH2 | 1.73, m | H-5 | C-4, 5, 7 | H-4α |
| 1.95, m | 1.64, m | H-5 | C-4, 5, 7 | ||||
| 7 | 26.5, CH2 | 1.40, m | 26.1, CH2 | 1.26, brs | |||
| 8 | 26.5, CH2 | 1.22, brs | 28.6, CH2 | 1.26, brs | |||
| 9 | 29.4, CH2 | 1.22, brs | 28.9, CH2 | 1.26, brs | |||
| 10 | 29.2, CH2 | 1.22, brs | 28.8, CH2 | 1.26, brs | |||
| 11 | 29.2, CH2 | 1.22, brs | 28.7, CH2 | 1.26, brs | |||
| 12 | 29.4, CH2 | 1.22, brs | 31.6, CH2 | 1.26, brs | |||
| 13 | 22.7, CH2 | 1.22, brs | 22.1, CH2 | 1.26, brs | |||
| 14 | 14.1, CH3 | 0.88, t (6.5) | 14.0, CH3 | 0.86, t (6.8) | H-13 | C-12, 13 | |
| 1′ | 136.1, C | - | 137.4, C | - | |||
| 2′ | 129.4, CH | 7.31, m | 129.1, CH | 7.31, m | C-1 | H-1a, 1b, H2 | |
| 3′ | 128.9, CH | 7.35, m | 128.5, CH | 7.34, m | C-1 | ||
| 4′ | 127.2, CH | 7.25, m | 126.6, CH | 7.26, m | C-2′, 6′ | ||
| 5′ | 128.9, CH | 7.31, m | 128.5, CH | 7.34, m | C-1 | ||
| 6′ | 129.4, CH | 7.35, m | 129.1, CH | 7.31, m | C-1 | H-1a, 1b, H2 | |
| N-CH3 | 36.7, CH3 | 2.81, s | - | - | |||
| OH-3 | - | 5.12, d (11.7) | - | 5.62, d (4.0) | H-3 | C-2, 3, 4 | H-1a, 3, 4β |
Figure 3ORTEP view of a protonated 5a.
Figure 4The minimal APDF (Amplitude Probability Density Function) DFT (Density Functional Theory) energy molecular model of amino-protonated 5b, in its (2S, 3S, 5R) configuration. The other 17 models tested differ in the conformation of the ring and in the orientations of the hydroxyl and -CH2-C6H6 substituent groups.
Figure 5Experimental (solid line) and simulated (dotted line) methanol ECD (Electronic Circular Dichroism) spectra of 5b. The simulated spectrum of the (2S, 3S, 5R) model configuration fits well the experimental data.
Figure 6Gram-positive bacteria biofilm biomass production after 24 h of incubation with different concentrations of compound 5a. Data are shown as Mean ± SD of the three independent experiments. One-sample t test: ** p < 0.01 and *** p < 0.001, significantly different from 100%. MIC, minimum inhibitory concentration.
Fractional inhibitory concentration (FIC) index of 5a in combination with clinically relevant antibiotics obtained by the checkerboard method.
| Bacterial Strain | 5a-Van | 5a-Ox | ||
|---|---|---|---|---|
| ΣFIC | Activity | ΣFIC | Activity | |
| 0.4 | S | - | - | |
| - | - | 0.2 | S | |
S = synergism; VAN = vancomycin; OX = oxacillin.
Combined effect of colistin with 5a against colistin resistant E. coli strain 1410/1. MICs for colistin are expressed in µg/mL.
| Compound | µg/mL of 5a + Colistin | |||||||
|---|---|---|---|---|---|---|---|---|
| Colistin (MIC) | 8 R | 8 R | 8 R | 4 R | 1 S | 0.016 S | <0.008 S | <0.008 S |
MIC = minimum inhibitory concentration; R = resistant; S = sensitive.
Percentage of cell viability relative to control of 1a, 2a–e, 3, 4, 5a, b, 6 (100 µM) and crude extract of A. candidus KUFA 0062 (200 µg/mL) in eight human cancer cell lines after 48 h of incubation as assessed by MTT assay.
The results are the mean (SD) of at least four independent experiments, each in duplicate. Significant differences (** p < 0.01; *** p < 0.001 and **** p < 0.0001) when compared with control cells were evaluated by one-way ANOVA, followed by the post-hoc Dunnett’s test. # Indicates significant differences when 5b is compared with 5a, as evaluated by a t-test. Compounds/extract are marked in light gray when cell viability is equal to or greater than 50% and in dark gray when cell viability is lower than 50% relative to control. n.d.—not determined.
IC50 values (half-maximal inhibitory concentration) and respective 95% confidence intervals of compounds tested in eight human cancer cell lines, determined by the MTT assay.
| IC50 (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Compounds (µM) | HepG2 | HT29 | HCT116 | A549 | A375 | MCF7 | U251 | T98G |
|
| 56.3 | 34.8 | 60.8 | 84.1 | 82.8 | 94.8 | n.d. | n.d. |
| (37.9–83.7) | (22.0–55.0) | (41.6–88.8) | (60.3–117.1) | (50.5–123.8) | (63.2–142.3) | |||
|
| 123.8 | 113.7 | 72.9 | 109.0 | 146.4 | n.d. | n.d. | n.d. |
| (86.4–177.5) | (78.9–163.8) | (56.0–94.9) | (66.2–179.5) | (102.3–209.4) | ||||
|
| 118.9 | 111.6 | 73.2 | 105.8 | 123.1 | 186.8 | 212.5 | n.d. |
| (88.9–159.0) | (85.9–145.0) | (59.3–90.4) | (72.8–153.7) | (91.9–164.9) | (155.1–224.8) | (156.2–289.2) | ||
|
| n.d. | 43.2 | 64.1 | 85.2 | 109.8 | 99.7 | 120.2 | n.d. |
| (28.3–65.7) | (42.9–95.7) | (61.9–117.3) | (76.4–157.6) | (70.8–143.0) | (81.2–177.7) | |||
|
| 43.2 | 12.3 | 29.8 | 47.9 | 38.5 | 53.6 | 74.1 | 50.4 |
| (30.7–60.8) | (10.1–15.5) | (19.1–46.6) | (33.2–69.0) | (29.8–49.7) | (39.4–72.9) | (54–0–101.6) | (32.0–79.4) | |
|
| 153.4 | 57.2 | 124.8 | 215.7 | 148.5 | 128.8 | 128.6 | – |
| (96.2–244.7) | (41.7–78.4) | (94.9–164.1) | (161.4–288.1) | (103.7–212.4) | (94.5–175.5) | (86.7–190.8) | ||
|
| 0.12 | 0.63 | 0.29 | 0.24 | 0.05 | 0.36 | 1.11 | 15.4 |
| (0.07–0.22) | (0.26–1.12) | (0.16–0.54) | (0.13–0.08) | (0.03–0.08) | (0.16–0.84) | (0.43–2.85) | (10.4–22.9) | |
n.d.: IC50 not determined because no cytotoxicity was observed at 100 µM. IC50 values (in µM) are the mean of at least four independent experiments, each in duplicate. Doxorubicin (Dox) was used.